Modulation of NAD+ metabolic pathways for treatment of disease
US10722529B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2016 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Dec 2, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/048
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.